MALCOLM BRENNER to Adenoviridae
This is a "connection" page, showing publications MALCOLM BRENNER has written about Adenoviridae.
Connection Strength
3.261
-
Mesenchymal Stromal Cells for Linked Delivery of Oncolytic and Apoptotic Adenoviruses to Non-small-cell Lung Cancers. Mol Ther. 2015 Sep; 23(9):1497-506.
Score: 0.388
-
Targeted delivery of adenoviral vectors by cytotoxic T cells. Blood. 2004 Oct 15; 104(8):2272-80.
Score: 0.180
-
Response to "systemic adenovirus delivery". Mol Ther. 2002 Aug; 6(2):138.
Score: 0.159
-
Bilamellar cationic liposomes protect adenovectors from preexisting humoral immune responses. Mol Ther. 2002 Mar; 5(3):233-41.
Score: 0.154
-
Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphoma. Cancer Gene Ther. 2001 May; 8(5):378-87.
Score: 0.146
-
Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas. J Immunother Cancer. 2021 05; 9(5).
Score: 0.146
-
Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors. Commun Biol. 2021 03 19; 4(1):368.
Score: 0.145
-
Phase I study of chemokine and cytokine gene-modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma using an adenoviral vector. Hum Gene Ther. 2000 Jul 01; 11(10):1477-88.
Score: 0.138
-
Reports of adenovector "death" are greatly exaggerated. Mol Ther. 2000 Mar; 1(3):205.
Score: 0.134
-
Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors. Mol Ther. 2020 05 06; 28(5):1251-1262.
Score: 0.134
-
Gene transfer by adenovectors. Blood. 1999 Dec 15; 94(12):3965-7.
Score: 0.133
-
IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood. 1998 Sep 15; 92(6):1941-9.
Score: 0.122
-
Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer. Mol Ther. 2017 11 01; 25(11):2440-2451.
Score: 0.113
-
Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors. Cancer Res. 2017 04 15; 77(8):2040-2051.
Score: 0.109
-
3D modeling of human cancer: A PEG-fibrin hydrogel system to study the role of tumor microenvironment and recapitulate the in vivo effect of oncolytic adenovirus. Biomaterials. 2016 Apr; 84:76-85.
Score: 0.101
-
Comparison of two CD40-ligand/interleukin-2 vaccines in patients with chronic lymphocytic leukemia. Cytotherapy. 2011 Oct; 13(9):1128-39.
Score: 0.074
-
Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-gamma. J Immunother. 2009 Jun; 32(5):524-38.
Score: 0.064
-
Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood. 2009 Aug 27; 114(9):1958-67.
Score: 0.064
-
Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol. 2008 Jan; 82(1):546-54.
Score: 0.057
-
Comparison of the efficiency of transduction of leukemic cells by fiber-modified adenoviruses. Hum Gene Ther. 2004 Dec; 15(12):1229-42.
Score: 0.047
-
Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cells. Blood. 2004 Oct 15; 104(8):2432-40.
Score: 0.046
-
Liposomal enhancement of the antitumor activity of conditionally replication-competent adenoviral plasmids. Mol Ther. 2004 Apr; 9(4):489-95.
Score: 0.045
-
Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications. Blood. 2004 Feb 01; 103(3):1011-9.
Score: 0.043
-
Bystander transfer of functional human CD40 ligand from gene-modified fibroblasts to B-chronic lymphocytic leukemia cells. Hum Gene Ther. 2003 Apr 10; 14(6):545-59.
Score: 0.042
-
Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies. Sci Adv. 2023 03 29; 9(13):eade6790.
Score: 0.042
-
Adenovector-induced expression of human-CD40-ligand (hCD40L) by multiple myeloma cells. A model for immunotherapy. Exp Hematol. 2001 Aug; 29(8):952-61.
Score: 0.037
-
Efficient infection of primitive hematopoietic stem cells by modified adenovirus. Gene Ther. 2001 Jun; 8(12):930-7.
Score: 0.037
-
Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes. Hum Gene Ther. 2001 Apr 10; 12(6):659-70.
Score: 0.036
-
Inhibition of glioma cells in vitro and in vivo using a recombinant adenoviral vector containing an astrocyte-specific promoter. Cancer Gene Ther. 2000 Aug; 7(8):1120-6.
Score: 0.035
-
T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T Cells. Clin Cancer Res. 2019 12 15; 25(24):7340-7350.
Score: 0.033
-
Gene and cell transfer for specific immunotherapy. Vox Sang. 1998; 74 Suppl 2:87-90.
Score: 0.029
-
HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. JAMA Oncol. 2017 Aug 01; 3(8):1094-1101.
Score: 0.028
-
Bortezomib sensitizes non-small cell lung cancer to mesenchymal stromal cell-delivered inducible caspase-9-mediated cytotoxicity. Cancer Gene Ther. 2014 Nov; 21(11):472-482.
Score: 0.023
-
Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol. 2014 Mar 10; 32(8):798-808.
Score: 0.022
-
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013 Oct 24; 122(17):2965-73.
Score: 0.021
-
Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther. 2013 Nov; 21(11):2113-21.
Score: 0.021
-
Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013 Jun 27; 121(26):5113-23.
Score: 0.021
-
Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. Blood. 2010 Apr 01; 115(13):2695-703.
Score: 0.017
-
Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host. Mol Ther. 2009 Sep; 17(9):1616-25.
Score: 0.016
-
Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006 Oct; 12(10):1160-6.
Score: 0.013
-
The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease. J Immunother. 2004 Jul-Aug; 27(4):317-27.
Score: 0.011
-
Selection of chronic lymphocytic leukemia binding peptides. Cancer Res. 2003 Sep 01; 63(17):5213-7.
Score: 0.011
-
Expansion of EBV latent membrane protein 2a specific cytotoxic T cells for the adoptive immunotherapy of EBV latency type 2 malignancies: influence of recombinant IL12 and IL15. Cytotherapy. 2003; 5(3):231-40.
Score: 0.010
-
Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus--positive Hodgkin's lymphoma. Int J Cancer. 2001 Sep 01; 93(5):706-13.
Score: 0.009
-
Vectors in cancer therapy: how will they deliver? Cancer Gene Ther. 1995 Dec; 2(4):291-7.
Score: 0.006